ANAHEIM, Calif., Aug. five, 2019 /PRNewswire/ — A new study shows that a particular person taking the medicinal cannabis derivative cannabidiol ( CBD) won’t fail a drug test for marijuana—but a particular person taking the emerging sleep help cannabinol (CBN) will. These findings have been presented these days at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo, and could avoid men and women from becoming unfairly penalized for making use of CBN.
CBD and CBN are each cannabis derivatives that have been gaining consideration for their capability to confer possible overall health rewards without the need of causing intoxication. The wellness business has exploded with CBD-primarily based merchandise that claim to aid situations ranging from anxiousness to acne, and final year, the Meals and Drug Administration authorized the 1st CBD-primarily based drug for the remedy of serious epilepsy. Even though CBN is not as effectively recognized however as CBD, extra men and women are also beginning to use it as a sleep help. With the recognition of these compounds increasing, it is important for healthcare providers to have an understanding of how CBD and CBN interact with screening tests for drug abuse. As just 1 instance of why this is crucial, particular healthcare institutes do not let individuals to use marijuana if they are taking opioids for discomfort management. If these individuals test falsely constructive for marijuana use due to CBD or CBN, they could be unfairly denied their prescriptions as a outcome.
A study group led by Grace Kroner, PhD, of the University of Utah Wellness Sciences Center in Salt Lake City, has elucidated how non-intoxicating cannabis derivatives react with immunoassays, which are the most popular form of drug screening test. The group spiked 3 distinctive batches of clean urine with 1000 ng/mL every of CBD and CBN, in addition to 1000 ng/mL every of two extra cannabis compounds that could have therapeutic rewards: cannabichromene (CBC) and cannabigerol (CBG). The researchers then tested the distinctive urine batches with two immunoassays named the Microgenics MultiGent Cannabinoids test and the Beckman Coulter Emit II Plus Cannabinoid test. For all 3 batches, neither test made a false-constructive outcome in reaction to CBD, CBC, or CBG. On the other hand, the Emit II Plus showed notable reactivity with CBN. Additional investigation revealed that as small as 100 ng/mL of CBN triggers a false constructive for marijuana use with this test.
Thanks to these findings, healthcare institutes that use these two tests will be in a position to interpret drug test outcomes with higher accuracy. Just as importantly, this study also demonstrates that distinctive drug screening tests make variable results—and that test suppliers and healthcare institutes alike will need to assess the cross-reactivity of their tests to defend individuals from false constructive drug screens.
“These findings will aid with interpreting drug screening immunoassay outcomes,” mentioned Kroner. “If physicians and laboratorians know a patient is taking CBN, they can take into account that if they get a constructive from an immunoassay. On the flip side, providers can also be extra particular when they get a constructive marijuana outcome that it’s not due to pure CBD oil alone. These outcomes are constantly assay dependent, although, so the field wants to hold this in thoughts.”
Session Information and facts
AACC Annual Scientific Meeting registration is totally free for members of the media. Reporters can register on the internet right here: https://www.xpressreg.net/register/aacc0819/media/landing.asp
Abstract B-264: Comparative Cross-reactivity in THC Immunoassays will be presented for the duration of the following two sessions:
AACC Student Poster Contest (Component two): Poster Presentations
Monday, August five
two:15 – three:30 p.m.
Scientific Poster Session
Wednesday, August 7
9:30 a.m. – five p.m. (presenting author in attendance from 12:30 – 1:30 p.m.)
Each sessions will take spot at the Anaheim Convention Center in California.
About the 71st AACC Annual Scientific Meeting & Clinical Lab Expo
The AACC Annual Scientific Meeting presents five days packed with possibilities to find out about thrilling science from August four-eight. Plenary sessions function the most recent study on accelerating the clinical adoption of new biomedical discoveries, the influence of genetics and brain circuitry on behavior, targeted breast cancer remedy, advances in precision medicine, and really speedy molecular diagnostic tests.
At the AACC Clinical Lab Expo, extra than 800 exhibitors will fill the show floor of the Anaheim Convention Center in California with displays of the most recent diagnostic technologies, such as but not restricted to mobile overall health, molecular diagnostics, mass spectrometry, point-of-care, and automation.
Committed to reaching greater overall health by means of laboratory medicine, AACC brings with each other extra than 50,000 clinical laboratory experts, physicians, study scientists, and business enterprise leaders from about the planet focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other regions of progressing laboratory science. Given that 1948, AACC has worked to advance the popular interests of the field, giving applications that advance scientific collaboration, expertise, experience, and innovation. For extra info, check out www.aacc.org.
Senior Manager, Communications & PR
Senior Director, Communications & PR
View original content material to download multimedia:http://www.prnewswire.com/news-releases/cbd-the-most recent-wellness-craze-wont-trigger-customers-to-fail-a-drug-testbut-its-lesser-recognized-cousin-cbn-will-300896599.html
Supply: https://www.ptcommunity.com/wire/cbd-most recent-wellness-craze-wont-trigger-customers-fail-drug-test-its-lesser-recognized-cousin-cbn-will